PPP1R1B and breast carcinoma: The expression of DARPP-32 in 230 breast cancer patients has been examined previously using N-terminal and C-terminal specific antibodies, to show that high N-terminal DARPP-32 expression is associated with adverse patient survival; this differs from the results presented here21.